|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park CH, Song KY and Kim SN: Treatment
results for gastric cancer surgery: 12 years' experience at a
single institute in Korea. Eur J Surg Oncol. 34:36–41. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with
S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Curiel TJ, Wei S, Dong H, Alvarez X, Cheng
P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et
al: Blockade of B7-H1 improves myeloid dendritic cell-mediated
antitumor immunity. Nat Med. 9:562–567. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Strome SE, Dong H, Tamura H, Voss SG,
Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al:
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous
cell carcinoma. Cancer Res. 63:6501–6505. 2003.PubMed/NCBI
|
|
7
|
Thompson RH, Gillett MD, Cheville JC,
Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen
L, et al: Costimulatory B7-H1 in renal cell carcinoma patients:
Indicator of tumor aggressiveness and potential therapeutic target.
Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+ T cells infiltrated within
cancer cell nests as a prognostic factor in human colorectal
cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
9
|
Schumacher K, Haensch W, Röefzaad C and
Schlag PM: Prognostic significance of activated CD8(+) T cell
infiltrations within esophageal carcinomas. Cancer Res.
61:3932–3936. 2001.PubMed/NCBI
|
|
10
|
Nakano O, Sato M, Naito Y, Suzuki K,
Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H and Ohtani H:
Proliferative activity of intratumoral CD8(+) T-lymphocytes as a
prognostic factor in human renal cell carcinoma: Clinicopathologic
demonstration of antitumor immunity. Cancer Res. 61:5132–5136.
2001.PubMed/NCBI
|
|
11
|
Li X, Kostareli E, Suffner J, Garbi N and
Hämmerling GJ: Efficient Treg depletion induces T-cell infiltration
and rejection of large tumors. Eur J Immunol. 40:3325–3335. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Antony PA, Piccirillo CA, Akpinarli A,
Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff
CA, Overwijk WW, et al: CD8+ T cell immunity against a
tumor/self-antigen is augmented by CD4+ T helper cells and hindered
by naturally occurring T regulatory cells. J Immunol.
174:2591–2601. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Workman CJ and Vignali DA: Negative
regulation of T cell homeostasis by lymphocyte activation gene-3
(CD223). J Immunol. 174:688–695. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rodig N, Ryan T, Allen JA, Pang H, Grabie
N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH and
Freeman GJ: Endothelial expression of PD-L1 and PD-L2
down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol.
33:3117–3126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keir ME, Freeman GJ and Sharpe AH: PD-1
regulates self-reactive CD8+ T cell responses to antigen in lymph
nodes and tissues. J Immunol. 179:5064–5070. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hirano F, Kaneko K, Tamura H, Dong H, Wang
S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al: Blockade of
B7-H1 and PD-1 by monoclonal antibodies potentiates cancer
therapeutic immunity. Cancer Res. 65:1089–1096. 2005.PubMed/NCBI
|
|
17
|
Huang B, Chen L, Bao C, Sun C, Li J, Wang
L and Zhang X: The expression status and prognostic significance of
programmed cell death 1 ligand 1 in gastrointestinal tract cancer:
A systematic review and meta-analysis. Onco Targets Ther.
8:2617–2625. 2015.PubMed/NCBI
|
|
18
|
Zhang L, Qiu M, Jin Y, Ji J, Li B, Wang X,
Yan S, Xu R and Yang D: Programmed cell death ligand 1 (PD-L1)
expression on gastric cancer and its relationship with
clinicopathologic factors. Int J Clin Exp Pathol. 8:11084–11091.
2015.PubMed/NCBI
|
|
19
|
Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH,
Kim SH, Chang H, Lee JO, Kim YJ, Lee HS, et al: Prognostic
implications of immunosuppressive protein expression in tumors as
well as immune cell infiltration within the tumor microenvironment
in gastric cancer. Gastric Cancer. 19:42–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Japanese Gastric Cancer Association:
Japanese Classification of Gastric Carcinoma-2nd English Edition.
Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Japanese Gastric Cancer Association:
Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric
Cancer. 14:113–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang R, Huang D, Dai W and Yang F:
Overexpression of HMGA1 correlates with the malignant status and
prognosis of breast cancer. Mol Cell Biochem. 404:251–257. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Urban JL and Schreiber H: Tumor antigens.
Annu Rev Immunol. 10:617–644. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takaya S, Saito H and Ikeguchi M:
Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on
CD4+ and CD8+ T Cells after gastric cancer surgery. Yonago Acta
Med. 58:39–44. 2015.PubMed/NCBI
|
|
26
|
Saito H, Kuroda H, Matsunaga T, Osaki T
and Ikeguchi M: Increased PD-1 expression on CD4+ and CD8+ T cells
is involved in immune evasion in gastric cancer. J Surg Oncol.
107:517–522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eto S, Yoshikawa K, Nishi M, Higashijima
J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T and Shimada
M: Programmed cell death protein 1 expression is an independent
prognostic factor in gastric cancer after curative resection.
Gastric Cancer. 19:466–471. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Thompson ED, Zahurak M, Murphy A, Cornish
T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, et
al: Patterns of PD-L1 expression and CD8 T cell infiltration in
gastric adenocarcinomas and associated immune stroma. Gut.
66:794–801. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun J, Xu K, Wu C, Wang Y, Hu Y, Zhu Y,
Chen Y, Shi Q, Yu G and Zhang X: PD-L1 expression analysis in
gastric carcinoma tissue and blocking of tumor-associated PD-L1
signaling by two functional monoclonal antibodies. Tissue Antigens.
69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu C, Zhu Y, Jiang J, Zhao J, Zhang XG and
Xu N: Immunohistochemical localization of programmed death-1
ligand-1 (PD-L1) in gastric carcinoma and its clinical
significance. Acta Histochem. 108:19–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
et al: CD8+ tumor-infiltrating lymphocytes together with CD4+
tumor-infiltrating lymphocytes and dendritic cells improve the
prognosis of patients with pancreatic adenocarcinoma. Pancreas.
28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Keir ME, Butte MJ, Freeman GJ and Sharpe
AH: PD-1 and its ligands in tolerance and immunity. Annu Rev
Immunol. 26:677–704. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arrieta O, Montes-Servin E,
Hernandez-Martinez JM, Cardona AF, Casas-Ruiz E, Crispin JC, Motola
D, Flores-Estrada D and Barrera L: Expression of PD-1/PD-L1 and
PD-L2 in peripheral T-cells from non-small cell lung cancer
patients. Oncotarget. 8:101994–102005. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu B, Yuan L, Gao Q, Yuan P, Zhao P, Yuan
H, Fan H, Li T, Qin P, Han L, et al: Circulating and
tumor-infiltrating Tim-3 in patients with colorectal cancer.
Oncotarget. 6:20592–20603. 2015.PubMed/NCBI
|
|
35
|
Saito H, Kono Y, Murakami Y, Shishido Y,
Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ashida K and Fujiwara
Y: Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1
expression. Anticancer Res. 38:107–112. 2018.PubMed/NCBI
|
|
36
|
Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan
J, Zhong X, Li X, Qian H and Wang X: PD-L1 and gastric cancer
prognosis: A systematic review and meta-analysis. PLoS One.
12:e01826922017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma C, Patel K, Singhi AD, Ren B, Zhu B,
Shaikh F and Sun W: Programmed death-ligand 1 expression is common
in gastric cancer associated with epstein-barr virus or
microsatellite instability. Am J Surg Pathol. 40:1496–1506. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Blank C, Gajewski TF and Mackensen A:
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T
cells as a mechanism of immune evasion: Implications for tumor
immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005.
View Article : Google Scholar : PubMed/NCBI
|
